Enzyme Immunoassay Market, By Product Type, By Specimen, By Application, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

REPORT HIGHLIGHT

Enzyme Immunoassay Market size was valued at USD 17,850.09 Million in 2024, expanding to a CAGR of 3.87% from 2025 to 2032.

Enzyme Immunoassay (EIA) is a biochemical analytical technique used to detect and quantify specific substances such as antigens, antibodies, hormones, proteins, or drugs by exploiting the high specificity of antigen antibody interactions. In this method, an enzyme is chemically linked to an antibody or antigen and acts as a signal generator. When the target molecule binds to its corresponding antibody, the attached enzyme catalyzes a reaction with an added substrate, producing a measurable signal, usually a color change, fluorescence, or luminescence.

Enzyme Immunoassay Market- Market Dynamics
Increasing prevalence of chronic, infectious diseases and expansion of diagnostic infrastructure are expected to propel market demand

The rising incidence of infectious diseases such as HIV, hepatitis, tuberculosis, and newly emerging viral infections is a key factor driving growth in the enzyme immunoassay market. Enzyme immunoassays are extensively used for early diagnosis, large-scale screening, and confirmatory testing because they offer high accuracy, strong specificity, and cost-effective performance. At the same time, the increasing prevalence of chronic diseases including cardiovascular diseases, cancer, autoimmune conditions, and diabetes has intensified the need for dependable and efficient diagnostic solutions. Enzyme immunoassays are essential for identifying disease-specific biomarkers, hormones, and antibodies, enabling timely diagnosis and continuous monitoring of disease progression. With healthcare systems worldwide placing greater emphasis on preventive care, early detection, and improved patient outcomes, the use of EIA-based diagnostic tests is steadily expanding across hospitals, clinical laboratories, and diagnostic centers across the globe.

Ongoing technological advancements in enzyme immunoassay platforms such as improved ELISA kits, greater automation, multiplex testing capabilities, and the development of more efficient enzymes and substrates, are significantly contributing to market expansion. Automated and semi-automated EIA systems enhance testing efficiency, minimize manual errors, and enable high-throughput analysis, making them especially appealing to modern clinical laboratories. In addition, the rapid development of healthcare and diagnostic infrastructure in emerging economies, driven by supportive government policies and increased private-sector investment, has broadened access to advanced diagnostic solutions. The expanding application of enzyme immunoassays in pharmaceutical research, vaccine development, and clinical trial activities is also boosting market demand. Collectively, technological innovation and infrastructure growth are accelerating the widespread adoption of enzyme immunoassays across clinical, research, and industrial settings worldwide.

Enzyme Immunoassay Market- Segmentation Analysis:

The Global Enzyme Immunoassay Market is segmented on the basis of Product Type, Specimen, Application, End User, and Region.

The market is divided into five categories based on Specimen: blood, urine, saliva, and others. Blood segment in the specimen is primarily held major share because of its high diagnostic reliability and broad clinical applicability. Blood-based samples provide higher concentrations of biomarkers such as antigens, antibodies, hormones, and proteins, enabling enzyme immunoassays to deliver superior sensitivity and specificity. The widespread use of blood tests in hospitals, diagnostic laboratories, and research settings further boosts this segment’s revenue share.

The market is divided into six categories based on Application: infectious diseases, cardiology, oncology, autoimmune disorders, therapeutic drug monitoring, and others. The infectious diseases segment held the majority market share in 2024, driven by the consistently high prevalence and incidence of infectious diseases across the globe. Conditions such as HIV/AIDS, hepatitis B and C, tuberculosis, influenza, and other viral and bacterial infections continue to pose significant public health challenges, particularly in densely populated and developing regions. This sustained disease burden has created strong demand for accurate, rapid, and cost-effective diagnostic methods.

Enzyme Immunoassay Market- Geographical Insights

Across the globe, the Enzyme Immunoassay market is split in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America accounts for the substantial share of the enzyme immunoassay market, driven by its advanced laboratory infrastructure, substantial healthcare expenditure, early adoption of automated immunoassay technologies, and the strong presence of major diagnostic companies. Followed by Europe which is supported by robust public healthcare systems, widespread routine screening programs, and increasing emphasis on early detection of infectious and chronic diseases. The Asia Pacific region represents the fastest-growing market, propelled by expanding access to healthcare services, a rising burden of diseases, greater awareness of early diagnostic testing, and significant investments in laboratory infrastructure by both governments and private players, particularly in countries such as China and India. Latin America is experiencing steady growth due to ongoing improvements in healthcare infrastructure and increasing volumes of diagnostic testing.

Italy Enzyme Immunoassay Market- Key Insights

China stands out as a major country in the Asia Pacific region and rapidly expanding country-level market within the enzyme immunoassay (EIA) sector. Growth is largely fueled by its vast population, the rising incidence of infectious and chronic diseases, and a growing need for timely and accurate diagnostic solutions. Government-led efforts to enhance public healthcare systems, broaden disease screening initiatives, and upgrade laboratory infrastructure have significantly accelerated the uptake of enzyme immunoassays in hospitals and diagnostic centers. Additionally, the strong expansion of China’s biotechnology and pharmaceutical industries has increased the use of EIAs in areas such as drug discovery, vaccine development, and clinical research. Greater awareness of preventive healthcare, along with increasing adoption of automated and high-throughput immunoassay technologies, continues to drive steady and long-term growth of the EIA market in China.

Enzyme Immunoassay Market- Competitive Landscape:

The enzyme immunoassay (EIA) market is characterized by intense competition, with a mix of global healthcare conglomerates and specialized diagnostic companies competing to strengthen their market positions. Leading players such as Siemens Healthineers, Danaher Corporation, Bio-Rad Laboratories, bioMérieux SA, and QuidelOrtho maintain strong competitiveness through extensive product portfolios, advanced immunoassay platforms, and well-established global distribution networks. These companies focus heavily on continuous innovation, offering automated and high-throughput enzyme immunoassay systems that improve laboratory efficiency, accuracy, and turnaround times. Significant investments in research and development enable them to regularly introduce new and improved assay kits targeting infectious diseases, chronic conditions, and specialized diagnostic applications.

Recent Developments:

In 2025, Revvity Inc. introduced the IDS i20, a fully automated chemiluminescence immunoassay solution, empowering multi-specialty testing on a single system which enhance workflow efficiency for clinical labs.
In February 2025, VION Biosciences completed the acquisition of BioAssay Systems, a company known for its expertise in high-throughput enzyme immunoassay technologies. This strategic move enhanced VION’s footprint in the diagnostics and life sciences tools.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ENZYME IMMUNOASSAY MARKET KEY PLAYERS

Siemens Healthineers
Danaher Corporation
Thermo Fisher Scientific
F. Hoffmann-La Roche AG
Abbott Laboratories
Bio-Rad Laboratories
bioMérieux SA
QuidelOrtho Corporation
Becton, Dickinson and Company
Sysmex Corporation
PerkinElmer (Revvity)
Agilent Technologies
Merck KGaA
DiaSorin S.p.A.
Randox Laboratories
VION Biosciences
Others

GLOBAL ENZYME IMMUNOASSAY MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019-2032

Reagents & Kits
Instruments
Software & Services

GLOBAL ENZYME IMMUNOASSAY MARKET, BY SPECIMEN- MARKET ANALYSIS, 2019-2032

Blood
Urine
Saliva
Others

GLOBAL ENZYME IMMUNOASSAY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019-2032

Infectious diseases
Cardiology
Oncology
Autoimmune disorders
Therapeutic drug monitoring
Others

GLOBAL ENZYME IMMUNOASSAY MARKET, BY END USER- MARKET ANALYSIS, 2019-2032

Hospitals
Diagnostic Laboratories
Pharmaceutical & Biotech Companies
Academic Research
Others

GLOBAL ENZYME IMMUNOASSAY MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA Show more